Lancet: abrocitinib monodrug is used in the treatment of moderate to severe adhesion it.

!---- is an oral selective Janus kinase 1 inhibitor that is effective and well tolerated in adults with moderate to severe adhesion dermatitis in Stage 2b trials.researchers recently assessed the effectiveness and safety of Abrocitinib's single drug for the treatment of moderate and severe adhesitis in adolescents and adults.JADE MONO-1 is a Phase III clinical study, and patients over 12 years of age with moderate to severe adhesion dermatitis were randomly received at 100 mg, 200 mg abrocitinib or a placebo, once daily for 12 weeks.common endpoint is the proportion of patients who received an overall assessment response (defined as a score of 0 (cleared) or 1 (almost cleared), and an improvement of 2 degrees over the baseline) and a rate of at least 75% higher than the baseline in the EASI-75 score.387 patients participated in the study, 156 patients received 100 mg of abrocitinib treatment, 154 patients received 200 mg of abrocitinib treatment, and 77 patients received a placebo.12th week, the proportion of patients in the 100 mg abrocitinib group who achieved the overall assessment response was significantly higher than in the placebo group (37 out of 156 patients vs 76 patients), and the proportion of patients with the overall assessment response in the abrocitinib 200 mg group was significantly higher than the overall assessment group (6 out of 67 out of 153 patients).the proportion of patients in the abrocitinib 100 mg group (62/156 vs 9/76) and abrocitinib 200 mg group (96/153 vs 9/76) received an EASI-75 response at the 12th week was significantly higher than that of the placebo group.108 (69%) of 156 patients in the 100mg group of abrocitinib had adverse events, 120 (78%) of 154 patients in the abrocitinib 200mg group had adverse events, and 44 (57%) of 77 patients in the placebo group had adverse events.5 (3%) of 156 patients in the 100mg group of abrocitinib had severe adverse events, 5 (3%) of 154 patients in the abrocitinib 200mg group had severe adverse events, and 3 (4%) of 77 patients in the placebo group had severe adverse events. No treatment-related deaths have been reported.oral abrocitinib is effective and well tolerated once a day for patients with moderate to severe epidermatitis in adolescents and adults..